Advertisement

Topics

Cyclacel Pharma Announces Selection Of Recommended Phase II Dose For CYC065 And Evidence Of Durable Target Engagement And Mcl-1 Biomarker Suppression

20:00 EDT 6 Aug 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Cyclacel Pharma Announces Selection Of Recommended Phase II Dose For CYC065 And Evidence Of Durable Target Engagement And Mcl-1 Biomarker Suppression

NEXT ARTICLE

More From BioPortfolio on "Cyclacel Pharma Announces Selection Of Recommended Phase II Dose For CYC065 And Evidence Of Durable Target Engagement And Mcl-1 Biomarker Suppression"

Quick Search
Advertisement